Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417946 | 0.91 | KDM4E (0.72) | KDM4EALDH1A1HTTEPHX2LMNA | |
| SCHEMBL8959410 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1HTTLMNAPOLB | |
| SCHEMBL18389971 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HTTEPHX2LMNA | |
| SCHEMBL14257122 | 0.85 | KDM4E (0.45) | KDM4EALDH1A1HTTLMNAPOLB | |
| SCHEMBL24371200 | 0.85 | KDM4E (0.56) | KDM4EALDH1A1HTTEPHX2LMNA | |
| SCHEMBL13853824 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1HTTEPHX2LMNA | |
| SCHEMBL18389913 | 0.81 | HTT (0.69) | KDM4EALDH1A1HTTLMNAPOLB | |
| SCHEMBL8959413 | 0.81 | KDM4E (0.42) | KDM4EALDH1A1HTTPOLBP2RX4 | |
| SCHEMBL26826602 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1EPHX2HRH3 | |
| SCHEMBL26814552 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1HTTEPHX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | KDM4E 4719/4885ALDH1A1 918/4885HTT 4172/4885 |
| US-20090105476-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | KDM4E 3873/4885ALDH1A1 166/4885HTT 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.